Gabriela Gruia - 05 May 2023 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Director
Signature
/s/ John Hamill, Attorney-in-fact
Issuer symbol
APRE
Transactions as of
05 May 2023
Net transactions value
$0
Form type
4
Filing time
08 May 2023, 17:17:19 UTC
Previous filing
06 Jun 2022
Next filing
15 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Options (Right to Buy) Award $0 +12,500 $0.000000 12,500 05 May 2023 Common Stock 12,500 $3.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options shall vest in full on May 5, 2024, subject to the reporting person's continued service through and including the applicable vesting date.